Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Dig Dis Sci ; 69(2): 426-436, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38060167

RESUMO

BACKGROUND: We recently demonstrated that diarrhea-predominant irritable bowel syndrome (IBS-D) subjects have higher relative abundance (RA) of hydrogen sulfide (H2S)-producing Fusobacterium and Desulfovibrio species, and constipation-predominant IBS (IBS-C) subjects have higher RA of methanogen Methanobrevibacter smithii. AIMS: In this study, we investigate the effects of increased methanogens or H2S producers on stool phenotypes in rat models. METHODS: Adult Sprague-Dawley rats were fed high-fat diet (HFD) for 60 days to increase M. smithii levels, then gavaged for 10 days with water (controls) or methanogenesis inhibitors. To increase H2S producers, rats were gavaged with F. varium or D. piger. Stool consistency (stool wet weight (SWW)) and gas production were measured. 16S rRNA gene sequencing was performed on stool samples. RESULTS: In HFD diet-fed rats (N = 30), stool M. smithii levels were increased (P < 0.001) after 52 days, correlating with significantly decreased SWW (P < 0.0001) at 59 days (R = - 0.38, P = 0.037). Small bowel M. smithii levels decreased significantly in lovastatin lactone-treated rats (P < 0.0006), and SWW increased (normalized) in lovastatin hydroxyacid-treated rats (P = 0.0246), vs. controls (N = 10/group). SWW increased significantly in D. piger-gavaged rats (N = 16) on day 10 (P < 0.0001), and in F. varium-gavaged rats (N = 16) at all timepoints, vs. controls, with increased stool H2S production. 16S sequencing revealed stool microbiota alterations in rats gavaged with H2S producers, with higher relative abundance (RA) of other H2S producers, particularly Lachnospiraceae and Bilophila in F. varium-gavaged rats, and Sutterella in D. piger-gavaged rats. CONCLUSIONS: These findings suggest that increased M. smithii levels result in a constipation-like phenotype in a rat model that is partly reversible with methanogenesis inhibitors, whereas gavage with H2S producers D. piger or F. varium results in increased colonization with other H2S producers and diarrhea-like phenotypes. This supports roles for the increased RA of methanogens and H2S producers identified in IBS-C and IBS-D subjects, respectively, in contributing to stool phenotypes.


Assuntos
Sulfeto de Hidrogênio , Síndrome do Intestino Irritável , Humanos , Adulto , Ratos , Animais , Síndrome do Intestino Irritável/microbiologia , Metano , RNA Ribossômico 16S/genética , Ratos Sprague-Dawley , Constipação Intestinal/etiologia , Constipação Intestinal/microbiologia , Diarreia/microbiologia , Modelos Animais , Lovastatina
3.
Dermatol Clin ; 42(3): 377-386, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38796269

RESUMO

Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.


Assuntos
Adalimumab , Produtos Biológicos , Fármacos Dermatológicos , Psoríase , Ustekinumab , Humanos , Psoríase/tratamento farmacológico , Psoríase/terapia , Criança , Adalimumab/uso terapêutico , Produtos Biológicos/uso terapêutico , Ustekinumab/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Terapia Biológica , Infliximab/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Etanercepte/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Rituximab/uso terapêutico , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Alefacept , Certolizumab Pegol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA